Drug eruptions with novel targeted therapies – immune checkpoint and EGFR inhibitors

Summary

Given the increasing use of novel targeted therapies, dermatologists are constantly confronted with novel cutaneous side effects of these agents. A rapid diagnosis and appropriate management of these side effects are crucial to prevent impairment of the patients’ quality of life and interruptions of essential cancer treatments. Immune checkpoint and EGFR inhibitors are frequently used targeted therapies for various malignancies and are associated with a distinct spectrum of cutaneous adverse events. Exanthematous drug eruptions represent a particular diagnostic challenge in these patients. Immune checkpoint inhibitors can elicit a plethora of immune-related exanthemas, most commonly maculopapular, lichenoid, and psoriasiform eruptions. Additionally, autoimmune bullous dermatoses and exanthemas associated with connective tissue diseases may arise. In cases of severe, atypical or therapy-resistant presentations an extensive dermatological investigation including a skin biopsy is recommended. Topical and systemic steroids are the mainstay of treatment. Papulopustular eruptions represent the major cutaneous adverse effect of EGFR inhibitor therapy, occurring in up to 90% of patients within the first two weeks of therapy, depending on the agent. Besides topical antibiotics and steroids, oral tetracyclines are the first choice in systemic treatment and can also be used as prophylaxis.

Introduction

The increasing use of modern targeted therapies leads to the emergence of novel cutaneous side effects that must be diagnosed and managed appropriately. Immune checkpoint inhibitors and EGFR inhibitors are common targeted therapies, each with a specific cutaneous side effect profile.

The increasing use of modern targeted therapies has expanded available therapeutic options, especially in the field of oncology. Meanwhile, a large number of molecular targets for small molecules and monoclonal antibodies have been established. Such novel therapeutic approaches are frequently associated with novel cutaneous side effects. Exanthematous skin eruptions represent a particular challenge in this context due to the frequently necessary polypharmaceutical therapy. Benign exanthemas in late-type reactions, and the much rarer severe drug rashes caused by known medications, have already been covered in previous CME articles [1, 2]. It is, however, important to detect novel drug associated eruptions, differentiate them from other diagnoses, and manage them appropriately. Immune checkpoint inhibitors and inhibitors of the epidermal growth factor receptor (EGFR) are frequently and increasingly used in day-to-day clinical practice. Therefore, this CME article focuses on exanthemas associated with these drugs, including differential diagnoses and therapeutic options. With early diagnosis and adequate therapy, these cutaneous side effects can often be well controlled, thus avoiding impairment of the patient’s quality of life as well as disruption of effective oncological therapy.

© 2021 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft. | JDDG | 1610-0379/2021/1911
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Immune checkpoint inhibitors

Blockade of inhibitory immunological checkpoints with CPI (immune checkpoint inhibitors), referred to as immunotherapy in oncology, is increasingly used in various malignant diseases. Immune checkpoint inhibitors target either CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) or PD-1 (programmed cell death protein 1), or its ligands (PD-L1). Based on their activating effect on the immune system, CPI are associated with a novel and diverse spectrum of cutaneous immune-related adverse events (irAE). These occur in 47–60% of patients treated with CTLA-4 inhibitors and in 30–40% of patients treated with PD-1/PD-L1 inhibitors [3]. Cutaneous irAE usually appear within the first few weeks after initiation of treatment, sometimes directly after the first administration [3, 4]. Cutaneous irAE are thus the most common and the earliest occurring immune-related side effects.

The spectrum of possible skin reactions associated with immunotherapy is large and ranges from various inflammatory responses to bullous eruptions (Table 1) [5]. Non-specific pruritic maculopapular skin reactions are the most common forms. The eruptions may, however, also resemble well-known inflammatory dermatoses and are thus termed “lichenoid” or “psoriasiform” exanthemas. Exanthematous

Table 1 Overview of the most important exanthemas associated with checkpoint inhibitor immunotherapy, timing of onset and differential diagnosis.

| Average latency after treatment initiation until skin eruptions occur (weeks) |
|-----------------------------|--------|
| Non-bullous exanthemas      |        |
| Maculopapular exanthemas    | 2–6    |
| Lichenoid exanthemas        | ~12    |
| Psoriasiform exanthemas     | 0–4 (pre-existing psoriasis) ~12 (initial manifestation) |
| Connective tissue disease-associated exanthemas |
| – Dermatomyositis           | Unknown (reports from week 0) |
| – Cutaneous lupus erythematosus | ~10 |
| Morbus Grover-like exanthemas | 3–6 |
| Selection of important differential diagnoses: |
| – Drug eruptions caused by other medications: antibiotics, analgetics, etc. |
| – Infectious exanthemas     |        |
| Bullous Exanthemas          |        |
| Bullous pemphigoid          | ~24    |
| Bullous lichenoid exanthemas| ~12    |
| Stevens-Johnson Syndrome/toxic epidermal necrolysis | 0–4 (cases with delayed appearance have been reported) |
| Selection of important differential diagnoses: |
| – Severe bullous drug eruptions caused by other medications: allopurinol, sulfonamides, anticonvulsants etc. |
| – Bullous infectious exanthemas: Staphylococcal Scalded Skin Syndrome (SSSS), bullous impetigo, herpes simplex/zoster |
| – Mechanical blisters (pressure/tension blisters) |
Immune-related cutaneous adverse events usually do not impair continuation of immunotherapy.

The most common skin reactions with immune checkpoint inhibitors are non-specific maculopapular exanthemas that resemble the ‘classic’ maculopapular drug rashes.

Maculopapular exanthemas

Non-specific maculopapular exanthemas appear in about 10–25% of patients within 2–6 weeks after treatment initiation, and sometimes even after the very first administration of CPI. They occur more frequently and earlier with combined therapy and with CTLA-4 inhibitors than with PD-1/PD-L1 inhibitors. These exanthemas are usually mild. The clinical appearance shows bright red macules and papules, mainly on the trunk, while the face as well as the palms and soles are spared. Pruritus and mild scaling may be present [5]. Histopathology frequently shows perivascular lymphocytic infiltration in the superficial dermis, sometimes with eosinophils and spongiosis [14]. A careful anamnesis regarding medication is essential to exclude other drugs as possible elicitors of a maculopapular drug eruption (such as antibiotics). Non-specific maculopapular skin lesions may also constitute the initial manifestation of specific exanthemas or severe drug reactions, so patients need to be monitored accordingly.

Lichenoid exanthemas

Case report 1: A 76-year-old male patient reported severely pruritic, generalized skin lesions mainly on the extensor sides of the upper and lower limbs that had appeared a few weeks earlier (Figure 1). The trunk was only sparsely affected, and the mucous membranes were normal. Due to adenocarcinoma of the left upper lobe of the lung, the patient was treated with localized radiation and, for the last ten months, with a PD-1 inhibitor (pembrolizumab). He was also on continuous medication with enalapril, bisoprolol, aspirin, and fenofibrate for various medical conditions.

Lichenoid exanthemas are a common feature of immunotherapy-associated skin reactions. They mainly occur in association with PD-1/PD-L1 inhibitors; up to 17% of patients show this reaction [5, 13]. Lichenoid skin lesions may be under-diagnosed, and some authors consider them to be the most common clinical and/or histopathological pattern of inflammatory cutaneous irAE [11, 16]. Lichenoid exanthemas appear weeks or even months (on average 12 weeks) after treatment initiation, and thus later than maculopapular exanthemas [17].

Clinical appearance varies. Exanthemas may consist of classic lichenoid papules with Wickham striae that can also coalesce into larger plaques, but can also
present with less specific maculopapular skin lesions or resemble hypertrophic lichen ruber planus (LRP) with hyperkeratotic plaques (Figure 1). Pronounced pruritus is often reported. The skin lesions may appear localized or generalized. Bullous lesions, palmoplantar manifestations, and involvement of the mucous membranes may occur [5, 18]. Immune-mediated bullous lichenoid exanthemas, especially with involvement of the oral mucous membranes, are an important differential diagnosis to severe bullous drug reactions [7]. For a differential diagnosis, other pharmaceutical causes of lichenoid drug eruptions as well as idiopathic lichenoid LRP need to be considered. Medications that frequently cause lichenoid drug eruptions include cardiological medications (beta blockers, diuretics) as well as antimalarials and tumor necrosis factor (TNF)α blockers. As opposed to the predilection sites of classic LRP (flexor sides of the limbs), in lichenoid drug rashes the lesions more commonly appear on the extensor sides of the limbs including the backs of the hands, and in areas exposed to light. Morphology often shows a comparatively pronounced eczematous component with scaling. Diagnosis of lichenoid drug eruptions is made more difficult by the fact that they appear late – up to several months after treatment initiation – and that they clear up only slowly after the putative causal agent has been discontinued [19]. Allergological diagnostics, such as epicutaneous tests, are rarely successful [20]. If lichenoid skin lesions appear within the first few months after initiation of PD-1/PD-L1 treatment, association with the immunotherapy is probable due to the reported frequency. Premature discontinuation of essential medications for internal diseases should be avoided.

Histopathology usually cannot differentiate between immunotherapy-associated lichenoid exanthemas and idiopathic LRP [14]. The classic appearance shows irregular acanthosis and hypergranulosis with a subepithelial band-like lymphocytic epidermotropic inflammatory infiltration associated with melanophages and vacuolar degeneration, up to subepithelial fissures (bullous forms) at the dermoepidermal junction zone [14]. Occasional reports have described a comparative accumulation of CD163⁺ macrophages and CD4⁺ lymphocytes, as well as increased histological variability with spongiosis, eosinophiles, and parakeratosis, which are not typical for LRP, as indicative [14, 17].

Figure 1 Symmetrically distributed violaceous papules and plaques predominantly affecting the extensor surfaces of the limbs (a, b) and arms (c). An overlying, reticulated, fine white scale is visible (b, c).

Figure 1

Lichenoid drug eruption may appear several months after treatment initiation. There is no certain way to distinguish them from idiopathic exanthematous lichen ruber, either clinically or histopathologically.
Continuation of Case report 1: A skin biopsy showed the histological signs of lichen ruber verrucosus (Figure 2) and the patient was diagnosed with pembrolizumab-associated lichenoid exanthemas. He received topical corticosteroids (class IV), UVB phototherapy, and retinoids (acitretin). The skin lesions resolved over a period of several months until they disappeared completely. Pembrolizumab therapy was discontinued upon complete response of the tumor due to the dermatological side effect. The patient has remained tumor-free for two years.

Erythemasquamous and papulosquamous exanthemas

Psoriasiform exanthemas are mainly associated with PD-1/PD-L1 inhibitors [5, 11]. They can occur either de novo or as an exacerbation of pre-existing psoriasis [11, 16, 21, 22]. In the latter case, exanthematous skin lesions will frequently appear within the first month of treatment, while de novo manifestations usually occur later, about three months after treatment initiation [21]. The clinical appearance usually shows plaque-type psoriasis; other subtypes such as palmoplantar, pustular, guttate, erythrodermic, or inverse psoriasis are rare [21–23]. Papulosquamous exanthemas occurring in association with immunotherapy may also resemble pityriasis rubra pilaris [24].

Bullous pemphigoid

Immunotherapy-associated bullous pemphigoid is mostly seen with PD-1/PD-L1 inhibitors and tends to occur late, on average six months after treatment initiation [25, 26]. As in the general population, bullous pemphigoid is the most common autoimmune bullous dermatosis associated with immunotherapy. It is, however, still a rare side effect, and is seen in about 0.9 % of patients [15, 25, 26]. For comparison: Its incidence in the general population is 7.6 per 100,000 per year, though this increases significantly with age [27].

Similarly to the classic form, the pre-bullous stage shows severely pruritic urticarial to maculopapular erythemas, with the typical firm subepidermal blisters appearing in the later course of the disease [28]. The oral mucous membranes may also be involved [28, 29]. Any treatment-refractory pruritic erythema associated...
Differential diagnoses of treatment-refractory pruritic lesions associated with immunotherapy must include the pre-bullous stage of a bullous pemphigoid.

with immunotherapy may actually be a bullous pemphigoid in the pre-bullous stage – a possibility that should always be considered in differential diagnosis.

Histopathology and immunopathology mostly resemble the classic bullous pemphigoid: Histopathological examination typically shows subepidermal fissures of varying severity as well as dermal inflammatory infiltration of lymphocytes, eosinophils, and neutrophils. Direct immunofluorescence shows linear deposits of C3 and/or IgG along the dermoepithelial junction zone [14]. Auto-antibodies against BP180 are found in up to three-quarters of all patients in serological analysis, while antibodies against other components of the dermoepidermal junction zone are much rarer [30]. Negative results on auto-antibodies, however, do not rule out the diagnosis [29, 30].

As a differential diagnosis, other bullous exanthemas reported in association with immunotherapy should also be considered, such as bullous lichenoid exanthemas [7, 31], lichen planus pemphigoides [32–34], or severe bullous drug reactions [7, 35, 36]. Clinically, the firm blisters of bullous lichenoid exanthemas are only found on lichenoid plaques. They develop due to pronounced interface dermatitis with subepidermal fissures [32]. In contrast, lichen planus pemphigoides shows firm blisters not only in classic lichenoid plaques but also on skin areas without lichenoid lesions. These are caused by secondary autoantibody formation, similar to bullous pemphigoid [32].

In addition, bullous eruptions must be distinguished from diseases in the pemphigus group. These, however, can be considered a rarity in patients with immunotherapy: There are only a few individual case reports on paraneoplastic pemphigus being revealed or newly occurring in patients receiving immunotherapy [37, 38]. This may be due to the fact that paraneoplastic pemphigus is a rare disease that occurs most frequently (84 %) in hematological disorders, which are currently not an indication for immunotherapy [39]. To date, cases of classic pemphigus vulgaris have not been reported.

Connective tissue disease-associated exanthemas

Case report 2: After the second treatment cycle of combined chemo-immunotherapy with pembrolizumab, pemetrexed, and carboplatin, a 56-year-old female patient with metastasized bronchial carcinoma experienced slightly pruritic skin lesions starting in the cleavage area. After the fourth cycle, about ten weeks after treatment initiation, she noticed pronounced exacerbation spreading over the whole body (Figure 3). The mucous membranes remained normal.

Exanthematous skin lesions under immunotherapy may indicate newly occurring autoimmune connective tissue diseases (collagenoses). These side effects are rare, with cutaneous lupus erythematosus (LE) and dermatomyositis as the main examples.

Appearance of cutaneous LE, most commonly subacute cutaneous lupus erythematosus (SCLE), has been reported from two weeks to several months (about ten weeks on average) after initiation of PD-1/PD-L1 inhibitor treatment [6, 40–43]. Epidemiological data are scarce; in a small cohort of patients with PD-1/PD-L1 inhibitor treatment the incidence of drug-induced LE was estimated at 0.5 % [41]. For comparison: The incidence of SCLE in the general population is estimated at 0.6 per 100,000, with drug association likely playing a role in up to one-third of cases [44, 45]. The work of Marzano et al. [46] provides a good overview of drug-induced LE. SCLE is the most common variant, ahead of systemic LE. Drug-induced SCLE is frequently associated with diuretics, antihypertensives, proton pump inhibitors, antifungal medications, TNFα blockers, and more
recently PD-1/PD-L1 inhibitors. The clinical picture shows sometimes extensive, annular or papulosquamous plaques mostly in areas exposed to light. Vesiculobul-
lous forms as well as forms resembling erythema multiforme have been reported. In drug-induced SCLE, antinuclear antibodies (ANA) and SSA(Ro) antibodies are frequently positive and anti-histone antibodies are negative. Internal organs are usually not affected.

Histology in cutaneous LE is characterized by interface dermatitis, perivascu-
lar and periadnexial lymphocytic infiltrations, thickening of the basement membrane, epidermal atrophy, and dermal mucin deposits [47]. The extent of the individual features varies between the clinical subtypes, with fluent transitions. Diagnosis thus requires a clinico-pathological correlation [47]. Histopathology alone cannot clearly distinguish between systemic and cutaneous LE, nor can it differentiate LE from dermatomyositis [47].

Newly occurring dermatomyositis in a patient on immunotherapy can present with pronounced skin lesions typical for this disease, including Gottron papules, heliotropic periorbital erythema, and extensive erythema on the trunk and limbs, particularly in areas exposed to light. Muscular complaints may also occur. Symptoms quite frequently start shortly after treatment initiation, sometimes even after the very first administration of CPI [48, 49]. ANA are often positive while myositis-specific auto-antibodies may be missing [48]. In many cases, myositis-specific auto-antibodies are antibodies against transcriptional intermediary factor-1γ (TIF-1γ) [49–51], which is associated with paraneoplastic dermatomyositis [52].

Apart from primary induction due to the medication, it is also possible that latent auto-immune processes may be revealed (unmasked) by this treatment. This appears especially plausible in cases of dermatomyositis with a paraneoplasia-as-
sociated auto-antibody profile. There has been one report on exacerbation of an-
ti-TIF-1γ antibody-positive paraneoplastic dermatomyositis, which had previously remained subtle and undiagnosed, after initiation of immunotherapy [53].

Continuation Case report 2: Skin biopsy (Figure 4) as well as laboratory ana-
lyses were performed for further assessment. The patient showed ANA at high titers (1 : 1280) and SSA antibodies but negative dsDNA antibodies. There were no clinical or laboratory indications of organ involvement. After clinico-pathological
correlation, SCLE due to pembrolizumab therapy (CTCAE III) was diagnosed. Systemic treatment with prednisolone at 1 mg per kg body weight was initiated and topical steroid treatment commenced. This led to resolution of the skin lesions, and the prednisolone was tapered off over a period of several weeks. The immunotherapy was discontinued due to the dermatological side effects.

Severe cutaneous drug reactions

Severe bullous drug reactions such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) have been reported as very rare side effects of immunotherapy [7, 11, 35, 54]. They typically present with rapidly progressive, coalescing, dark red macules and atypical cockades with blistering, positive Nikolski phenomenon, and hemorrhagic-erosive involvement of the mucous membranes [35]. Frequently, in cases of first-time use the causative medication was initiated within the last four weeks. With CPI treatment, as well, most of the reactions occurred after the first or second administration [35]. The long half-life of substances like pembrolizumab may explain why reactions occur three weeks after first administration or shortly after the second dose. Individual case reports on delayed severe bullous drug reactions after immunotherapy have also been published. In these cases, non-specific maculopapular exanthemas preceded the bullous lesions [35, 36]. Reschke et al. [7], however, suggested that some of the SJS/TEN case reports from the literature should rather be categorized as bullous lichenoid drug eruptions. Due to a number of histopathological and clinical overlaps, it can be quite difficult to differentiate SJS/TEN from the much more common bullous lichenoid exanthemas. However, the latter present with slower clinical progression, less severe involvement of the mucous membranes, and a better prognosis. Histopathology in SJS/TEN shows cytotoxic interface dermatitis with varying epidermal necrosis and sparse lymphocytic dermal infiltration [14]. On the other hand, acanthosis, hypergranulosis, and a more prominent lichenoid lymphocytic infiltration favor the diagnosis of lichenoid drug eruption [7, 14].

For differential diagnosis, a careful anamnesis of medications is essential to identify other possible causes for SJS/TEN such as allopurinol, sulfonamides, or...
Exanthema to immune checkpoint and EGFR inhibitors

Exanthema to immune checkpoint and EGFR inhibitors

Aromatic anticonvulsants. Bullous autoimmune dermatoses and staphylococcal scalded skin syndrome (SSSS) need to be excluded [7].

There are only a few individual case reports on other severe cutaneous drug reactions with immunotherapy such as DRESS syndrome (drug reaction with eosinophilia and systemic symptoms) or AGEP (acute generalized exanthematous pustulosis) [57, 58]. Other well-conducted case reports and case series are needed before these can be categorized as rare immunotherapy-associated drug reactions.

Other exanthematous skin reactions

Morbus-Grover-like exanthema with pruritic papules and papulovesicles mainly on the trunk has been reported in association with CPI treatment, frequently occurring within the first 3–6 weeks after treatment initiation [5, 59].

Succulent erythematous plaques and fever in temporal connection with immunotherapy may indicate Sweet Syndrome. Cases were usually reported in patients on ipilimumab treatment (a CTLA-4 inhibitor) [60–62].

Immune checkpoint inhibitors are increasingly used in patients with allogenic stem cell transplants, for example in recurrent or treatment refractory Hodgkin’s lymphoma. This appears to be associated with an increased risk of graft-versus-host disease (GvHD), especially of severe acute GvHD, and needs to be considered in these patients [63, 64]. Acute GvHD on the skin frequently presents with pruritus and a generalized maculopapular exanthema originating from painful palmoplantar and retroauricular erythema. Accompanying symptoms often include hepatopathy and gastrointestinal involvement (tenesmus, watery diarrhea, vomiting), which may facilitate differentiation from classic drug rashes and chemotherapy side effects such as hand-foot syndrome. It is also necessary to exclude infectious causes including viral exanthemas in these patients [65].

Apart from these exanthematous effects, immunotherapy may also have other cutaneous irAE such as sarcoid-like reactions [66–68], vitiligo, particularly in patients with malignant melanoma, or pruritus.

Diagnostic procedure

If immunotherapy-associated exanthema is suspected, the first diagnostic step is to exclude alternative causes such as drug rash caused by other medications, or infectious exanthema. Occurrence of skin reactions within the first weeks or months after initiation of immunotherapy supports a CPI-associated origin once differential diagnoses have been excluded (Table 1).

Maculopapular exanthema may also be a precursor of more specific exanthemas or severe cutaneous drug reactions. Severe, treatment-refractory, or atypical exanthemas therefore always require a comprehensive dermatological investigation including skin biopsy (histology and direct immunofluorescence) and case-specific laboratory analyses. The appearance of known warning signs for severe cutaneous drug reactions (fever, swelling of face and lymph nodes, eosinophilia, involvement of the mucous membranes, grayish skin with increased sensitivity to pain, epidermal detachment, erosions) necessitates rapid assessment [69].

If exanthemas mainly appear in areas exposed to light, the patient must be examined for other skin reactions that may indicate connective tissue disease. Histological and laboratory analyses including ANA, SSA-/SSB, dsDNA, anti-histone and myositis antibodies as well as determination of creatinine kinase levels in case of muscle complaints, are recommended in these cases.
In cases of bullous skin reactions or skin lesions with pronounced, treatment-refractory pruritus, bullous autoimmune dermatoses need to be excluded – especially bullous pemphigoid and its pre-bullous precursor. This requires a skin biopsy and serological evaluation including indirect immunofluorescence and determination of BP-180/BP-230 auto-antibodies.

**Treatment**

**General principles on treating cutaneous irAE**

Therapeutic management needs to be adapted to the severity of the cutaneous side effect according to the CTCAE classification, thus the grade of severity must routinely be evaluated and documented accordingly [4, 70]. The CTCAE classification version 5 offers detailed grading for various cutaneous side effects. Extent of the affected body surface, severity of associated symptoms, and patients’ impairment of daily activities and quality of life are the most important criteria for grading [8]. Table 2 summarizes relevant criteria for immunotherapy-associated exanthemas and the corresponding therapeutic measures. While the CTCAE classification constitutes a valuable support tool for non-dermatologists, from a dermatological point of view a more precise characterization of cutaneous irAE according to the variants of immunotherapy-associated exanthemas described above is to be desired. This permits better assessment of the further course of the disease, and a more targeted choice of treatment. The diagnosis of SJS, for example, is described as a Grade III reaction in the CTCAE classification (Table 2) – a fact that definitely appears worthy of discussion from a dermatological point of view. SJS has completely different prognostic and therapeutic consequences than a maculopapular exanthema with the same grade of severity according to CTCAE.

The majority of cutaneous irAE, especially the most common maculopapular, lichenoid, and psoriasiform reactions, are rather mild (Grade I/II); they can be managed very well with early and appropriate topical treatment, and they do not usually require discontinuation of immunotherapy [11, 21].

For mild symptoms, temporary use of topical glucocorticoids (medium and high potency) is the basic recommended treatment. Discontinuation of immunotherapy and, if appropriate, systemic glucocorticoids are required for persistent and severe (Grade ≥ III) exanthemas (Table 2). Decisions on continuation of immunotherapy must be taken on an individual basis and by an interdisciplinary team. This decision needs to consider the present response to oncological treatment, the therapeutic goal (palliative or curative), the patient’s impairment of quality of life due to the cutaneous irAE, and the response to topical and systemic dermatological treatment. In cases of severe cutaneous adverse reaction, immunotherapy must always be discontinued [54].

A classic drug rash will usually resolve rapidly after withdrawal of the causative medication. In contrast, immune-related cutaneous adverse events may show a protracted and sometimes recurrent course even after withdrawal of the medication, due to the persistent immune-mediated effects [17, 28]. Maintenance therapy may be required, and relapses with increased disease activity may occur after further administrations of immunotherapy [11].

**Specific treatment measures**

In cases of specific dermatological manifestations, appropriate therapeutic options for the relevant dermatosis can be employed. This underscores the importance of
### Table 2 CTCAE grading (severity) scale for cutaneous drug eruptions and implications for the therapy of cutaneous immune-related adverse events associated with immune checkpoint inhibitors.

| Grade I (mild) | Grade II (moderate) | Grade III (severe) | Grade IV (life-threatening) | Grade V (death) |
|----------------|---------------------|--------------------|-----------------------------|-----------------|
| **Symptoms**   |                     |                    |                             |                 |
| – Skin eruptions < 10 % of BS | – Skin eruptions 10–30 % of BS or maculopapular/papulopustular exanthema | – Skin eruptions > 30 % of BS with moderate to severe concomitant symptoms (pain, pruritus) | – Skin eruptions > 30 % of BS with associated fluid/electrolyte imbalance | –                      |
| – no/mild concomitant symptoms | – Skin eruptions > 30 % of BS | – Erythroderma with mild concomitant symptoms (pruritus, pain) | – Treated in intensive care or burn unit | –                      |
| – asymptomatic erythroderma | – SJS (skin detachment < 10 % of BS) | – TEN (skin detachment > 30 % of BS) | – SJS/TEN overlap (skin detachment 10–30 % of BS) | –                      |
| – impaired IADL | – impaired BADL | –     | –                          | –                      |
| **Treatment of cutaneous irAE** [4] |                     |                    |                             |                 |
| – General measures (gentle skin care, avoiding UV exposure and skin irritation) | – General measures (gentle skin care, avoiding UV exposure and skin irritation) | – Topical glucocorticoids (high potency) | – Topical glucocorticoids (high potency) | –                      |
| – Topical glucocorticoids (low potency) | – Topical glucocorticoids (medium to high potency) | 0.5–1 mg/kg prednisolone; if improved: reduce dosage over a period of 2–4 weeks* | 1–2 mg/kg prednisolone; if improved: reduce dosage over a period of at least 4 weeks* | –                      |
| – Continue immunotherapy | – Continue immunotherapy with weekly monitoring; if no improvement: Treat as in Grade III | – Temporary discontinuation of immunotherapy; re-evaluate continuation if CTCAE ≤ Grade I/mild Grade II and prednisolone dose ≤ 10 mg | – Terminate immunotherapy | –                      |

**Abbr.:** BADL, basic activities of daily living (such as body care, eating); BS, body surface; CTCAE, Common Terminology Criteria for Adverse Events; IADL, instrumental activities of daily living (such as cooking, shopping, housework, use of transport); irAE, immune-related adverse event; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis.

*In verified cases of SJS/TEN: short-term systemic corticosteroid treatment ≤ 1 week, consider early administration of ciclosporin (3–5 mg/kg for 10 days).
Appropriate targeted and immunomodulatory treatment approaches may be employed for specific dermatological manifestations. These include phototherapy or retinoids for psoriasiform and lichenoid exanthema as well as dapsone or doxycycline for bullous pemphigoid. Characterizing exanthemas as clearly as possible. Since the patients have underlying malignant disease, immunomodulatory and targeted therapies are preferred. The idea is to mitigate any possible negative effect of broad immunosuppression on the antitumor efficacy of immunotherapy. The same concerns apply to the use of biologicals in this patient cohort, so due to the limited experience available they should only be used in treatment-refractory cases [22, 35, 71]. However, study data indicate that application of systemic glucocorticoids for treatment of irAE, at least, is not associated with an impaired prognosis [72].

For severe lichenoid exanthemas including bullous forms, specific treatments include retinoids or phototherapy – the latter with the exception of melanoma patients [18, 31]. For psoriasiform exanthemas that cannot be managed adequately by topical glucocorticoids or vitamin D3 analogs, phototherapy and retinoids are indicated as well. Apremilast and methotrexate are proven options as a subsequent therapeutic step [21, 22].

Protracted cases of SCLE occurring while on immunotherapy can be treated with hydroxychloroquine, and dermatomyositis with intravenous immunoglobulin [42, 46, 48, 49].

Discontinuation of immunotherapy often becomes necessary in cases of bullous pemphigoid or lichen planus pemphigoides. The decision if treatment should be continued must be taken individually [11, 26]; In mild cases, continuation of immunotherapy is possible with accompanying topical corticosteroids and frequent dermatological examinations [28, 29]. In severe cases, systemic glucocorticoids and discontinuation of immunotherapy are mandatory [23, 28]. Maintenance treatment is often indicated; immunomodulatory substances such as dapsone or doxycycline are appropriate medications [11, 26, 32]. Omalizumab has also been used successfully, especially in patients with increased total IgE [26, 73]. There are also some individual case reports on the use of rituximab, with varying success [29, 74, 75]. With continued maintenance treatment, reduction of the systemic steroid dose and re-introduction of immunotherapy may be feasible [26].

In confirmed cases of SJS/TEN, it is recommended to start medication with ciclosporin (3–5 mg/kg BW for 10 days) as early as possible, and limit systemic steroid treatment to just a few days [76, 77].

Inhibitors of the epidermal growth factor receptor (EGFR)

Case report 3: On the fifth day of treatment with the EGFR inhibitor erlotinib for metastasized lung cancer, a 73-year-old male patient developed a papulopustular exanthema on the upper back, the upper chest, and the face (Figure 5). He also reported mild pruritus.

EGFR inhibitors (EGFRI) are used for a broad range of oncological disease such as lung cancer, breast cancer, and gastrointestinal cancer as well as squamous cell carcinoma of the skin and the head and neck region. The EGFR pathway can be inhibited either in the extracellular or the intracellular space – extracellularly via parenteral administration of monoclonal antibodies, and intracellularly with oral ‘small molecules’.

EGFR is expressed in many parts of the skin, especially in the basal keratinocytes, the outer hair root sheath, the sweat glands, and the sebaceous glands [78]. EGFR inhibition leads to impaired differentiation of keratinocytes and epithelial cells in the skin appendages. This has been histopathologically shown in both affected and healthy skin [79, 80]. EGFR inhibition also resulted in an increased expression of pro-inflammatory cytokines and chemokines as well as a decrease of...
Exanthema to immune checkpoint and EGFR inhibitors

Antimicrobial peptides [79, 81]. The latter fact may explain the increased susceptibility to cutaneous superinfections seen with EGFR treatment, especially infections caused by *Staphylococcus aureus* [82]. EGFR is thus an important regulator for cutaneous homeostasis, and interventions in the EGFR pathway are associated with a typical range of cutaneous side effects.

Papulopustular exanthemas are the most common cutaneous side effects of EGFR inhibitors. After several weeks of treatment, about 30% of patients also develop xerosis cutis with a tendency towards asteatotic eczema. Other cutaneous side effects include pruritus, increased photosensitivity, and hair disorders (trichomegaly, alopecia, hirsutism) [83]. One particularly distressing side effect is painful paronychia, which occurs in 17% of patients around two months after treatment initiation, especially on the big toes [84, 85]. Initially, the nail affection is sterile, but bacterial and fungal superinfections are common [85]. The typical temporal course of cutaneous side effects with EGFR is depicted in Figure 6.

Exanthemas in the framework of severe cutaneous adverse reactions are a rarity with EGFR treatment. Very few individual case reports exist on severe bullous drug reactions (SJS/TEN) with osimertinib [86–88], afatinib [89, 90], and cetuximab [91, 92].

**Papulopustular exanthemas**

Papulopustular exanthemas occur in up to 90% of patients with EGFR treatment, especially with monoclonal antibodies and afatinib.

Papulopustular exanthema is the most common cutaneous side effect of EGFR. Asteotic eczema, paronychia, and hair disorders may also occur.

Papulopustular exanthemas occur in up to 90% of patients with EGFR treatment, especially with monoclonal antibodies and afatinib.

Figure 5 Follicular papulopustular eruption with emphasis on seborrheic and UV-exposed areas on the upper back, chest (a) and face (b, c).

Papulopustular exanthemas are the most common cutaneous side effects of EGFR inhibitors. Severity is also graded according to the CTCAE criteria (Table 2) [8]. Papulopustular exanthemas occur more frequently (70–90%) with monoclonal antibodies and afatinib (a second-generation tyrosine kinase inhibitor with irreversible and broad inhibition of the entire ErbB receptor family), and they are also more severe (Grade III/IV exanthemas in 10–15%) [93]. With other tyrosine kinase inhibitors, especially third-generation substances (such as osimertinib), skin reactions appear to occur less frequently and to be milder [94, 95].

Clinically, follicular papules and pustules will appear within two weeks of treatment initiation (Figure 5). Seborrheic areas and those exposed to UV radiation are affected while regions with previous radiation therapy remain spared [96]. Despite the frequently used term “acneiform rash”, the eruption, as opposed to classic acne, lacks the typical blackheads while dysesthesia and pruritus are common [83]. With continued therapy, the papulopustules will become
encrusted, partly in a hemorrhagic manner, and a slow improvement of the symptoms occurs [83]. After resolution, the affected areas frequently show erythema with telangiectasia, xerosis cutis, and less frequently post-inflammatory hyperpigmentation [79].

Due to the close temporal correlation and the characteristic clinical appearance there is usually no difficulty with differential diagnoses. However, other drugs may also cause “drug acne”, albeit less frequently (Table 3) [97]. The clinical picture in these cases also shows monomorphic papular to papulopustular skin lesions (initially without blackheads) with abrupt onset at an age untypical for acne vulgaris and sometimes spreading beyond the seborrheic areas [97]. In cases of atypical clinical appearance and further course, infectious folliculitis must be excluded via microbiological diagnostics.

**Prognosis**

Various studies have shown that patients with EGFRI-associated papulopustular exanthema actually responded better to oncological therapy [98, 99]. Tentative approaches to find the optimal dose by increasing dosage until papulopustular reactions appeared, however, did not result in any positive effects on overall survival, and have been rejected [100, 101]. If tolerated by the patient, papulopustular exanthema is therefore not a contraindication for continued therapy. However, a patient’s adherence to treatment may be impaired by the burdensome symptoms, so it is essential that the patient be informed about this side effect beforehand and that prophylactic measures are initiated already at the start of therapy.
Prophylaxis

The following prophylactic lifestyle and skincare measures are recommended:

- Use of emollient basic skin care with urea twice a day; only gentle, pH adjusted shower gels,
- Avoidance of mechanical, physical, and chemical skin irritation,
- Consistent use of sunscreen with high UV protection due to the treatment-associated, increased photosensitivity. However, sunscreen has no proven direct effect on EGFR-mediated papulopustular exanthemas [102].

For substances associated with a high incidence of papulopustular exanthema, tetracycline prophylaxis for at least eight weeks from the initiation of EGFR treatment can be recommended, while a “wait and see” approach may be justified for tyrosine kinase inhibitors with a low risk of exanthema.

Prophylactic use of tetracyclines (off label) is recommended in the S3 guideline of the German Cancer Society as a level B recommendation [93]. Its primary effect is a reduction of moderate/severe exanthema by 50–70 %, with only a small effect on the general incidence of exanthema [93, 103]. There were no negative effects regarding oncological treatment success, and a retrospective study even found a positive effect on overall survival with prophylactic tetracycline use [104, 105]. For prophylaxis, tetracyclines are administered at therapeutic doses from the initiation of EGFR treatment for at least eight weeks. Tetracycline prophylaxis appears to be particularly useful in cases with substances with a high incidence of papulopustular exanthema, while in cases with tyrosine kinase inhibitors with a low risk of exanthema a “wait and see” approach may be justified.

Treatment

External treatment with antibiotics and steroids, as well as systemic tetracyclines, are the mainstays of treatment.

External treatment of papulopustular exanthema alternates between topical antibiotics (1 % clindamycin, 0.75–2 % metronidazol, 1 % nadifloxacin) and topical medium to high-potency corticosteroids. “Classic” topical acne treatments such as benzoyl peroxide, azelaic acid, or retinoids are not recommended due to their drying effect. The same applies to topical calcineurin inhibitors. If no systemic prophylactic tetracycline treatment has been administered, this should be established.

| Drug class                  | Substances                                                                                                                                 |
|-----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| Steroids                    | Glucocorticoids, anabolic/androgenic steroids                                                                                                                                                      |
| Anti-tuberculosis drugs     | Isoniacide, rifampicin                                                                                                                                                                           |
| Neuropsychiatric therapies  | Lithium, anticonvulsants (phenytoin, carbamazepine, lamotrigine), aripiprazol                                                                                                                    |
| Vitamins                    | High-dose vitamin B1, B6, and B12                                                                                                                                                                 |
| Immunosuppressive treatments| Ciclosporin                                                                                                                                                                                          |
| Halogens                    | Bromine, iodine, chlorinated hydrocarbons                                                                                                                                                         |
| **Targeted therapies**      |                                                                                                                                                                                                     |
| EGFR inhibitors             | Monoclonal antibodies (cetuximab, panitumumab), small molecules (gefitinib, erlotinib, afatinib, dacomitinib, lapatinib, osimertinib)                                                              |
| MEK inhibitors              | Trametinib, cobimetinib                                                                                                                                                                            |
| Multi-tyrosine kinase inhibitors | Sorafenib, sunitinib, regorafenib, axitinib                                                                                               |
| mTOR inhibitors             | Sirolimus, everolimus, temsirolimus                                                                                                                                                                |
| Proteasome inhibitors       | Bortezomib                                                                                                                                                                                            |

*Abbr.: EGFR, epidermal growth factor receptor; mTOR, mechanistic target of rapamycin.*
(doxycycline 200 mg/day, lymecycline 300 mg/day, minocycline 100 mg/day). A response may be expected after 1–4 weeks, but there are no studies on optimum treatment duration. A pragmatic approach would be to consider discontinuation of the tetracyclines after eight weeks if the patient has responded well, or proactively continue treatment at a reduced dose (doxycycline 40 mg/day). The risk of relapses, however, will be increased since sub-antimicrobial doses are demonstrably associated with reduced efficacy [106]. For pustular skin lesions suspected of bacterial superinfection, a bacterial swab is recommended to detect tetracycline-resistant organisms. Appropriate antibiotic treatment according to the antibiogram, for example with first-generation cephalosporins, should then be established. In cases of severe exanthema (grade III/IV) and failure of tetracycline therapy, switching to low-dose isotretinoin (20–30 mg/day) and short-term systemic glucocorticoid treatment is an option. For CTCAE grade III onwards, the substance-specific summaries of product characteristics (SPC) on treatment discontinuation and dose modification need to be consulted [93, 107, 108].

Continuation Case report 3: Based on the clinical appearance and the temporal connection with initiation of erlotinib treatment, the diagnosis was “EGFRI-associated papulopustular exanthema” (CTCAE grade III). It was treated with systemic lymecycline 300 mg/day plus external clindamycin lotion and class III topical steroids. This resulted in a slow resolution of the pustular skin lesions. Erlotinib treatment was continued at a lower dose until the tumor progressed.

Conclusion

Due to the ongoing development of new targeted therapies, particularly in the field of oncology, dermatologists will continue to encounter new cutaneous side effects. Adequate diagnosis and management of these side effects are of great importance, not least because they can help ensure the success of oncological therapy by avoiding unnecessary breaks or discontinuation of immunotherapy. In view of the rapidly evolving medical literature, continuous and critical analysis of the publications is mandatory. It is not uncommon to find only single or incompletely documented case reports on rare cutaneous side effects, where the causal connection to a specific drug needs to be subsequently verified by well-documented case series and studies.

Acknowledgment

The authors are grateful to Dr. Petar Noack for his support in providing and evaluating the histopathological images.

References

1. Brandt O, Bircher AJ. Spättypreaktionen durch oral und parenteral applizierte Arzneimittel. J Dtsch Dermatol Ges 2017; 15: 1111–32.
2. Paulmann M, Mockenhaupt M. Schwere arzneimittelinduzierte Hautreaktionen: Klinik, Diagnostik, Ätiologie und Therapie. J Dtsch Dermatol Ges 2015; 13: 625–45.
3. Kumar V, Chaudhary N, Garg M et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 2017; 8: 49.
4. Haanen J, Carbonnel F, Robert C et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29: iv264–iv66.
5. Silbavid V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 2018; 19: 345–61.
6 Marano AL, Clarke JM, Morse MA et al. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy. Br J Dermatol 2019; 181: 580–3.
7 Reschke R, Mockenhaupt M, Simon JC et al. Severe bullous skin eruptions on checkpoint inhibitor therapy - in most cases severe bullous lichenoid drug eruptions. J Dtsch Dermatol Ges 2019; 17: 942–8.
8 US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0. National Institutes of Health, National Cancer Institute, 2017.
9 Belum VR, Benhuri B, Postow MA et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016; 60: 12–25.
10 Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23–34.
11 Coleman E, Ko C, Dai F et al. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol 2019; 80: 990–97.
12 Freeman-Keller M, Kim Y, Cronin H et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 2016; 22: 886–94.
13 Sanlorenzo M, Vujic I, Daud A et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 2015; 151: 1206–12.
14 Ellis SR, Vierra AT, Millsop JW et al. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features. J Am Acad Dermatol 2020; 83: 1130–43.
15 Hwang SJ, Carlos G, Wakade D et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD-1) therapy in patients with metastatic melanoma: A single-institution cohort. J Am Acad Dermatol 2016; 74: 455–61 e1.
16 Kaunitz GJ, Loss M, Rizvi H et al. Cutaneous eruptions in patients receiving immune checkpoint blockade: clinicopathologic analysis of the nonlichenoid histologic pattern. Am J Surg Pathol 2017; 41: 1381–9.
17 Tetzlaff MT, Nagarajan P, Chon S et al. Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the clinicopathologic features. Am J Dermatopathol 2017; 39: 121–9.
18 Shi VJ, Rodic N, Gettinger S et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol 2016; 152: 1128–36.
19 Brauer J, Votava HJ, Meehan S et al. Lichenoid drug eruption. Dermatol Online J 2009; 15: 13.
20 Merk HF, Vanstreels L, Megahed M. Lichenoid Arzneimittelreaktionen. Hautarzt 2018; 69: 116–20.
21 Bonigen J, Raynaud-Donzel C, Hureauux J et al. Anti-PD1-induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol 2017; 31: 6254–67.
22 Nikolaou V, Sibaud V, Fattore D et al. Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group. J Am Acad Dermatol 2021; 84: 1310–20.
23 Totonchy MB, Ezaldein HH, Ko CJ et al. Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma. JAMA Dermatol 2016; 152: 590–2.
24 Coleman E, Panse G, Haldas J et al. Pityriasis rubra pilaris-like erythroderma in the setting of pembrolizumab therapy responsive to acitretin. JAA D Case Rep 2018; 4: 669–71.
25 Curry JL, Tetzlaff MT, Nagarajan P et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol 2017; 44: 158–76.
26 Siegel J, Totonchy M, Damsky W et al. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. J Am Acad Dermatol 2018; 79: 1081–8.
27 Persson MSM, Harman KE, Vinogradova Y et al. Incidence, prevalence and mortality of bullous pemphigoid in England 1998–2017: a population-based cohort study. Br J Dermatol 2021; 184: 68–77.

28 Naidoo J, Schindler K, Querfeld C et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res 2016; 4: 383–9.

29 Sadik CD, Langan EA, Gutzmer R et al. Retrospective analysis of checkpoint inhibitor therapy-associated cases of bullous pemphigoid from six German dermatology centers. Front Immunol 2020; 11: 588582.

30 Tsiogka A, Bauer JW, Patsatsi A. Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: a review of the literature. Acta Derm Venereol 2021; 101: adv00377.

31 Wakade DV, Carlos G, Hwang Sj et al. PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases. Melanoma Res 2016; 26: 421–4.

32 Schmidgen MI, Butsch F, Schadmand-Fischer S et al. Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic melanoma. J Dtsch Dermatol Ges 2017; 15: 742–5.

33 Sato Y, Fujimura T, Mizuashi M et al. Lichen planus pemphigoides developing from patient with non-small-cell lung cancer treated with nivolumab. J Dermatol 2019; 46: E374–E5.

34 Senoo H, Kawakami Y, Yokoyama E et al. Atezolizumab-induced lichen planus pemphigoides in a patient with metastatic non-small-cell lung cancer. J Dermatol 2020; 47: E121–E2.

35 Coleman EL, Olamiju B, Leventhal JS. The life-threatening eruptions of immune checkpoint inhibitor therapy. Clin Dermatol 2020; 38: 94–104.

36 Vivar KL, Deschaine M, Messina J et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol 2017; 44: 381–4.

37 Yatim A, Bohelay G, Grootenboer-Mignot S et al. Paraneoplastic pemphigus revealed by anti-programmed death-1 pembrolizumab therapy for cutaneous squamous cell carcinoma complicating hidradenitis suppurativa. Front Med (Lausanne) 2019; 6: 249.

38 McNally MA, Vangipuram R, Campbell MT et al. Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma. JAAD Case Rep 2021; 10: 82–4.

39 Kaplan I, Hodak E, Ackerman L et al. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol 2004; 40: 533–62.

40 Bolton C, Chen Y, Hawthorne R et al. Systematic review: monoclonal antibody-induced subacute cutaneous lupus erythematosus. Drugs R D 2020; 20: 319–30.

41 Michot JM, Fusellier M, Champiat S et al. Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1. Ann Rheum Dis 2019; 78: E67.

42 Zitouni NB, Arnault JP, Dadban A et al. Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review. Melanoma Res 2019; 29: 212–5.

43 Liu RC, Sebaratnam DF, Jckett L et al. Subacute cutaneous lupus erythematosus induced by nivolumab. Australas J Dermatol 2018; 59: E152–E4.

44 Gronhagen CM, Fored CM, Granath F et al. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol 2011; 164: 1335–41.

45 Gronhagen CM, Fored CM, Linder M et al. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol 2012; 167: 296–305.

46 Marzano AV, Vezzoli P, Crosti C. Drug-induced lupus: an update on its dermatologic aspects. Lupus 2009; 18: 935–40.

47 Ribero S, Sciascia S, Borradori L et al. The cutaneous spectrum of lupus erythematosus. Clin Rev Allergy Immunol 2017; 53: 291–305.
48 Kosche C, Stout M, Sosman J et al. Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature. Mela-
noma Res 2020; 30: 313–6.
49 Osaki M, Tachikawa R, Ohira J et al. Anti-transcriptional intermediary factor 1-gamma antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report. Invest New Drugs 2021; 39: 251–5.
50 Yamaguchi Y, Aso M, Nagasawa H et al. Atezolizumab-associated dermatomyositis in advanced lung small-cell carcinoma. Intern Med 2021; 60(18): 3025–9.
51 Berger M, Legeay AL, Souci S et al. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma. Eur J Cancer 2018; 104: 227–30.
52 Fiorentino DF, Chung LS, Christopher-Stine L et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum 2013; 65: 2954–62.
53 Shibata C, Kato J, Toda N et al. Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report. J Med Case Rep 2019; 13: 168.
54 Chen CB, Wu MY, Ng CY et al. Severe cutaneous adverse reactions induced by target-
ed anticanicancer therapies and immunotherapies. Cancer Manag Res 2018; 10: 1259–73.
55 Lu J, Thuraisingam T, Chergui M et al. Nivolumab-associated DRESS syndrome: A case report. JAAD Case Rep 2019; 5: 216–8.
56 Mirza S, Hill E, Ludlow SP et al. Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome. Melanoma Res 2017; 27: 271–3.
57 Hwang SJ, Carlos G, Wakade D et al. Ipilimumab-induced acute generalized exan-
thematosus pustulosis in a patient with metastatic melanoma. Melanoma Res 2016; 26: 417–20.
58 Page B, Borradori L, Beltraminelli H et al. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab. J Eur Acad Dermatol Venereol 2018; 32: e256–e7.
59 Chen WS, Tetzlaff MT, Diwan H et al. Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from para-
neoplastic pemphigus-like to Grover-like lesions. J Cutan Pathol 2018; 45: 764–73.
60 Gormley R, Wanat K, Elentzas R et al. Ipilimumab-associated Sweet syndrome in a melanoma patient. J Am Acad Dermatol 2014; 71: e211–3.
61 Kyllö RL, Parker MK, Rosman I et al. Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma. J Am Acad Dermatol 2014; 70: e85–e66.
62 Pintova S, Sidhu H, Friedlander PA et al. Sweet’s syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma Res 2013; 23: 498–501.
63 Havercos BM, Abbott D, Hamadani M et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood 2017; 130: 221–8.
64 Ijaz A, Khan AY, Malik SU et al. Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Blood Marrow Transplant 2019; 25: 94–9.
65 Strong Rodrigues K, Oliveira-Ribeiro C, deAbreu Fiuza Gomes S et al. Cutaneous graft-
versus-host disease: diagnosis and treatment. Am J Clin Dermatol 2018; 19: 33–50.
66 Birnbaum MR, Ma MW, Fleisig S et al. Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma. JAAD Case Rep 2017; 3: 208–11.
67 Laroche A, Alarcon Chinchilla E, Bourgeault E et al. Erythema nodosum as the initial presenta-
tion of nivolumab-induced sarcoidosis-like reaction. J Cutan Med Surg 2018; 22: 627–9.
68 Suozzi KC, Stahl M, Ko CJ et al. Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Rep 2016; 2: 264–8.
69 Hoetzenecker W, Nageli M, Mehra ET et al. Adverse cutaneous drug eruptions: current understanding. Semin Immunopathol 2016; 38: 75–86.
70 Brahmer JR, Laczetti C, Schneider BJ et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36: 1714–68.
71 Esfahani K, Miller WH, Jr. Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med 2017; 376: 1989–91.
72 Petrelli F, Signorelli D, Ghidini M et al. Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers (Basel) 2020; 12(3): 546.
73 Singer S, Nelson CA, Lian CG et al. Nonbullous pemphigoid secondary to PD-1 inhibition. JAAD Case Rep 2019; 5: 898–903.
74 Sowerby L, Dewan AK, Granter S et al. Rituximab treatment of nivolumab-induced bullous pemphigoid. JAMA Dermatol 2017; 153: 603–5.
75 Virgen CA, Nguyen TA, Di Raimondo C et al. Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma. JAAD Case Rep 2020; 6: 193–7.
76 Grünwald P, Mockenhaupt M, Panzer R et al. Erythema multiforme, Stevens-Johnson syndrome/toxic epidermal necrolysis - diagnosis and treatment. J Dtsch Dermatol Ges 2020; 18: 547–53.
77 Roujeau JC, Mockenhaupt M, Guillaume JC et al. New evidence supporting cyclosporine efficacy in epidermal necrolysis. J Invest Dermatol 2017; 137: 2047–9.
78 Green MR, Couchman JR. Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition. J Invest Dermatol 1985; 85: 239–45.
79 Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6: 803–12.
80 Guttmann-Yassky E, Mita A, De Jonge M et al. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. Eur J Cancer 2010; 46: 2010–9.
81 Lichtenberger BM, Gerber PA, Holcman M et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med 2013; 5: 199ra11.
82 Eilers RE Jr. Gandhi M, Patel JD et al. Dermatologic infections in cancer patients treated with epidermal growth factor inhibitor therapy. J Natl Cancer Inst 2010; 102: 47–53.
83 Macdonald JB, Macdonald B, Golitz LE et al. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol 2015; 72: 203–18; quiz 19–20.
84 Garden BC, Wu S, Lacouture ME. The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 2012; 67: 400–8.
85 Robert C, Sibaud V, Mateus C et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol 2015; 16: e181–9.
86 Lin YT, Chu CY. Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer. Lung Cancer 2019; 129: 110–1.
87 Sato I, Mizuno H, Kataoka N et al. Osimertinib-associated toxic epidermal necrolysis in a lung cancer patient harboring an eGFR mutation—a case report and a review of the literature. Medicina (Kaunas) 2020; 56: 403.
88 Wang J, Cheng X, Lu Y et al. A case report of toxic epidermal necrolysis associated with AZD-9291. Drug Des Devel Ther 2018; 12: 2163–7.
89 Doesch J, Debus D, Meyer C et al. Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient. Lung Cancer 2016; 95: 35–8.
90 Nühnen VP, Schön MP, Mössner R. Stevens-Johnson syndrome/toxic epidermal necrolysis overlap in a NSCLC patient treated with afatinib. J Dtsch Dermatol Ges 2018; 16: 199–201.
91 Lin WL, Lin WC, Yang JY et al. Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer. J Clin Oncol 2008; 26: 2779–80.
92 Urosevic-Maiwald M, Harr T, French LE et al. Stevens-Johnson syndrome and toxic epidermal necrolysis overlap in a patient receiving cetuximab and radiotherapy for head and neck cancer. Int J Dermatol 2012; 51: 864–7.
93 Deutsche Krebsgesellschaft e.V. §3-Leitlinie – Supportive Therapie bei onkologischen Patient/Innen, Version 1.3. – Februar 2020. AWMF.
94 Chu CY, Choi J, Eaby-Sandy B et al. Osimertinib: A novel dermatologic adverse event profile in patients with lung cancer. Oncologist 2018; 23: 891–9.
95 Bachet JB, Peuvrel L, Bachmeyer C et al. Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review. Oncologist 2012; 17: 555–68.

96 Bossi P, Liberatoscioli C, Bergamini C et al. Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. Ann Oncol 2007; 18: 601–2.

97 Du-Thanh A, Kluger N, Bensalleh H et al. Drug-induced acneiform eruption. Am J Clin Dermatol 2011; 12: 233–45.

98 Petrelli F, Borgonovo K, Barni S. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol 2013; 8: 173–81.

99 Petrelli F, Borgonovo K, Cabiddu M et al. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer 2012; 78: 8–15.

100 Van Cutsem E, Li CP, Nowara E et al. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. Br J Cancer 2014; 111: 2067–75.

101 Van Cutsem E, Tejpar S, Vanbekevoort D et al. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol 2012; 30: 2861–8.

102 Jatoi A, Thrower A, Sloan JA et al. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (NC05C4). Oncologist 2010; 15: 1016–22.

103 Petrelli F, Borgonovo K, Cabiddu M et al. Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis. Br J Dermatol 2016; 175: 1166–74.

104 Alanen V, livanainen S, Arffman M et al. Tetracyclines increase the survival of NSCLC patients treated with EGFR TKIs: a retrospective nationwide registry study. ESMO Open 2020; 5: e000864.

105 Dascalu B, Kennecke HF, Lim HJ et al. Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer. Support Care Cancer 2016; 24: 799–805.

106 Vaubel J, Livingstone E, Schadendorf D et al. Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rash. J Eur Acad Dermatol Venereol 2014; 28: 1685–9.

107 Guggina LM, Choi AW, Choi JN. EGFR inhibitors and cutaneous complications: a practical approach to management. Oncology and Therapy 2017; 5: 135–48.

108 Lacouture ME, Anadkat MJ, Bensadoun RJ et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 2011; 19: 1079–95.
CME Questions/Lernerfolgskontrolle

1. Welche Aussage zu lichenoiden Arzneimittelexanthernem ist richtig?
   a) Bei Auftreten eines lichenoiden Arzneimittelexanthernems kann das auslösende Medikament durch eine allergologische Hauttestung mit großer Wahrscheinlichkeit identifiziert werden.
   b) Durch eine histopathologische Untersuchung kann ein lichenoides Arzneimittelexanthem sicher von einem klassischen Lichen ruber planus unterschieden werden.
   c) Im Gegensatz zum klassischen Lichen ruber planus tritt Juckreiz äußerst selten bei Immuntherapie-assoziierten lichenoiden Arzneimittelexanthernen auf.
   d) Immuntherapie-assoziierte lichenoid Arzneimittelexanthernem verlaufen häufig schwer.
   e) Lichenoide Exanthernem stellen eine relativ häufige immunvermittelte Nebenwirkung unter Checkpoint-Inhibitor-Therapie dar.

2. Welche Aussage zu kutanen immunvermittelten Nebenwirkungen unter Immuntherapie mit Checkpoint-Inhibitoren ist richtig?
   a) Sie stellen seltene immunvermittelte Nebenwirkung dar.
   b) Ein Auftreten von Immuntherapie-assoziierten Exanthernem bereits nach der ersten Checkpoint-Inhibitor-Gabe ist nicht möglich.
   c) Nach Absetzen der Immuntherapie bilden sich die Hautveränderungen häufig rasch und spontan zurück.
   d) Häufig sind die kutanen immunvermittelten Nebenwirkungen mild und beeinträchtigen die Therapiefortführung nicht.
   e) Exanthernem im Rahmen von neu aufgetretenen Kollagenosen sind die häufigste Manifestation von Immuntherapie-assoziierten Exanthernen.

3. Welche der folgenden autoimmunbullöse Dermatosen kommt am häufigsten unter Immuntherapie mit Checkpoint-Inhibitoren vor?
   a) Pemphigus vulgaris
   b) lineare IgA-Dermatose
   c) bullöses Pemphigoid
   d) paraneoplastischer Pemphigus
   e) Pemphigus foliaceus

4. Eine Patientin entwickelt zwei Wochen nach Einleitung einer PD-1-Inhibitor-Therapie ausgeprägte livide Erytheme mit Betonung der photoexponierten Areale (Dekolleté, Gesicht, Handrücken). Darüber hinaus wird eine zunehmende muskuläre Schwäche in den proximalen Extremitäten angegeben. Welche diagnostische Maßnahme trägt am wenigsten zur weiteren Diagnosefindung bei?
   a) Autoimmunserologie (ANA, Myositis-Antikörper)
   b) Hautbiopsie
   c) Bestimmung der Kreatininkinase
   d) Elektromyographie
   e) Abdomensonographie

5. Welche Aussage zu psoriasiformen Exanthernem unter Immuntherapie mit Checkpoint-Inhibitoren ist richtig?
   a) Unter PD-1/PD-L1-Inhibitor-Therapie kommt es nicht selten zu einer exanthematischen Exazerbation einer vorbekannten milden Psoriasis.
   b) Bei Auftreten einer Psoriasis unter PD-1/PD-L1-Therapie muss die Immuntherapie in der Regel abgebrochen werden.
   c) Bei Immuntherapie-assoziierten psoriasiformen Exanthernem stellen die modernen Biologika die Therapie der ersten Wahl dar.
   d) Die generalisierte pustulöse Psoriasis stellt unter Immuntherapie mit Checkpoint-Inhibitoren die häufigste Psoriasis-Verlaufsform dar.
   e) Eine Psoriasis Erstmanifestation unter Checkpoint-Inhibitor Therapie wurde bisher nicht beschrieben.

6. Welche Aussage zur Therapie von Immuntherapie-assoziierten Exanthernem ist richtig?
   a) Eine rasche und aggressive immunsuppressive Therapie ist notwendig.
   b) Der Einsatz von systemischen Glukokortikoiden zur Therapie von immunvermittelten Nebenwirkungen geht nachgewiesener Weise mit einer schlechteren Tumorprognose einher.
   c) Bei einem Immuntherapie-assozierten bullösen Pemphigoid stellt Rituximab die Therapie der ersten Wahl dar.
   d) Bei lichenoiden und psoriasiformen Exanthernem unter Immuntherapie sind Retinoide und eine Phototherapie kontraindiziert.
   e) Vor Wiedereinleitung der Immuntherapie wird empfohlen eine Prednisolonadosis von ≤ 10 mg zu erreichen.

7. Welche der folgenden ist keine bekannte kutane Nebenwirkung unter EGFR-Therapie?
   a) Exsikkationsekzeme
   b) Papulopustulöse Exanthernem
   c) Trichomegalie
   d) Paronychie
   e) Vitiligo

8. Welche Aussage zum Management von papulopustulösen Exanthernem unter EGFR-Therapie ist richtig?
   a) Prophylaktische Maßnahmen sind nicht möglich.
   b) Klassische Lokaltherapeutika für die Akne vulgaris wie Benzoylperoxid oder Retinoide stellen Therapien der ersten Wahl dar.
c) Bei Auftreten eines papulopustulösen Exanthems muss eine EGFR-Therapie sofort abgebrochen werden.

d) Topische Therapiemaßnahmen spielen in der Therapie von EGFR-assoziierten papulopustulösen Exantheme keine Rolle.

e) Bei fehlenden Kontraindikationen kann besonders bei monoklonalen EGFR-Antikörpern eine prophylaktische Therapie mit Tetrazyklinen ab Beginn der EGFR-Therapie angeboten werden.

9. Welches der folgenden Arzneimittel ist höchstwahrscheinlich nicht für das Entstehen von papulopustulösen Hautveränderungen verantwortlich?
   a) Glukokortikoide
   b) Aripiprazol
   c) Sirolimus
   d) Ciclosporin
   e) Ramipril

10. Welche Aussage zur klinischen Präsentation von papulopustulösen Hautveränderungen unter EGFR-Therapie ist richtig?
   a) Komedonen treten regelmäßig mit Beginn der papulopustulösen Hautveränderungen auf.
   b) Die papulopustulösen Exantheme treten meist erst nach mehreren Therapiemonaten auf.
   c) Pruritus und Dysästhesien sind häufige Begleitsymptome.
   d) Für die Patienten stellen sie nur selten eine Beeinträchtigung in ihrer Lebensqualität dar.
   e) Im Gegensatz zur Akne vulgaris finden sich die Hautveränderungen nicht in den seborrhoischen Arealen.

Lieber Leserinnen und Leser, der Einsendeschluss an die DDA für diese Ausgabe ist der 31. Dezember 2021. Die richtige Lösung zum Thema „Lichen Planus – ein Klinikleitfaden“ in Heft 6 (Juni 2021) ist: (1e, 2d, 3c, 4e, 5a, 6e, 7e, 8e, 9e, 10c).

Bitte verwenden Sie für Ihre Einsendung das aktuelle Formblatt auf der folgenden Seite oder geben Sie Ihre Lösung online unter http://jddg.akademie-dda.de ein.